Search the Newsreel

Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket

REGENXBIO reported Q2 2026 adjusted EPS of $0.43, significantly beating the $0.25 forecast, though revenue of $108.02 million missed estimates. Shares rose premarket due to a strengthened balance sheet, with pro forma cash exceeding $310 million after a $100 million AbbVie milestone and a …

Crane NXT (NYSE:CXT) Posts Q2 CY2026 Sales In Line With Estimates

Crane NXT (NYSE:CXT) reported Q2 CY2026 results, meeting revenue expectations with $493.2 million, a 22% year-on-year increase. The company's non-GAAP EPS of $1.10 beat analyst estimates by 6.3%, and management raised its full-year Adjusted EPS guidance. Despite strong revenue growth and backlog, the company …

Analysts Offer Insights on NA Companies: SPX (SPXC), Bluelinx Holdings (BXC) and SpaceX (SPCX)

Analysts have provided their insights on SPX (SPXC), Bluelinx Holdings (BXC), and SpaceX (SPCX). J.P. Morgan maintained a Buy rating for SPX with a $282.00 price target, D.A. Davidson maintained a Hold rating for Bluelinx Holdings with a $65.00 price target, and Mizuho Securities …

Crane NXT Releases Q2 2026 Financial Results

Crane NXT, Co. reported strong Q2 2026 financial results, with adjusted earnings of $1.10 per share, surpassing estimates, and revenue of $493.0M, a 22.0% increase year-over-year. The growth was driven by organic sales and robust demand in its Security & Authentication Technologies division. The …

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a tender offer to …

argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE announced the commencement of a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. This acquisition will make Forte Biosciences a wholly-owned subsidiary of argenx. Forte's Board of Directors has recommended that shareholders accept …

REGENXBIO Inc. Quarterly Earnings Report

Form 8K Regenxbio Inc For: 6 August By Investing.com

This article announces the filing of a Form 8K by Regenxbio Inc. on August 6th. The content of the Form 8K itself is not detailed, but the article contextualizes it within broader financial market news and data provided by Investing.com.

REGENXBIO reports Q2 2026: $108.0M revenue, $22.7M net income, cash pro forma >$310M

REGENXBIO announced strong financial results for Q2 2026, with revenues reaching $108.0 million and net income at $22.7 million. The company's cash position, including July 2026 milestone and offering proceeds, stands at over $313 million pro forma. Key upcoming catalysts include a BLA initiation …

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO Inc. reported its second quarter 2026 financial results, highlighting strong clinical execution and a solid cash runway. Key achievements include the AFFINITY DUCHENNE® trial meeting its primary endpoint, the initiation of the NAAVIGATE study for diabetic retinopathy, and FDA reaffirming the path forward …

Conestoga Capital Advisors Exited Crane NXT Co. (CXT) Amid Rising Integration Challenges

Conestoga Capital Advisors sold its position in Crane NXT, Co. (CXT) during Q2 2026, citing increased integration and execution risk following strategic acquisitions. The firm believes that near-term benefits are

symbol__ Stock Quote Price and Forecast

Crane NXT, Co. (CXT) is an industrial technology company specializing in secure technology solutions. The stock is currently trading in the middle of its 52-week range, experiencing a recent drop of 4.22% ($2.31) since its last close. Recent news includes a raise in FY26 …

Prinx Chengshan Sets August Board Meeting to Approve Interim Results and Dividend Plan

REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS

NXP Semiconductors N.V. (NXPI) Stock Price, News, Quote & History

This page provides a comprehensive overview of NXP Semiconductors N.V. (NXPI) stock, including its current price, recent news, and historical performance data. Key headlines discuss analyst downgrades due to China auto and AI risks, rumors of an acquisition of Ambarella, and strong Q2 earnings …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) and certain officers, alleging federal securities law violations. The lawsuit claims that REGENXBIO made false and misleading statements about the development and commercialization of its gene therapy RGX‑111, …

Hanx Biopharmaceuticals Sets Board Meeting to Approve Interim 2026 Results

Crane NXT reports improved sales of US$493 million in 2Q26 despite “lower volumes” from gaming payments arm CPI

Crane NXT, an industrial technology firm, reported a 22% year-on-year increase in sales to US$493 million in the June 2026 quarter, with net income up 42.2% to US$35.4 million and Adjusted EBITDA rising 18.0% to US$115.5 million. This growth occurred despite "lower volumes" from …

Bluelinx Holdings Inc. (BXC) Q2 FY2026 earnings call transcript

BlueLinx Holdings Inc. reported strong Q2 FY2026 results, with net sales up 4% year-over-year to $814 million and adjusted EBITDA increasing 33% to $35.6 million, despite a challenging housing market. The company attributed its success to disciplined execution, strategic product and channel strategies, and …

argenx (ENXTBR:ARGX) After Its Zacks Upgrade What Does The Valuation Narrative Say

Earnings Flash (CXT) Crane NXT, Co. Posts Q2 Adjusted EPS $1.10 per Share, vs. FactSet Est of $1.04

Crane NXT, Co. (CXT) reported its Q2 adjusted EPS at $1.10 per share, surpassing FactSet's estimate of $1.04. The company also announced Q2 revenue of $493.2 million, which exceeded FactSet's projection of $475.6 million. Crane NXT specializes in industrial technology, providing micro-optics for securing …

BlueLinx Q2 Earnings Call Highlights

Crane NXT (NYSE: CXT) lifts Q2 2026 revenue 22% on recent deals

Crane NXT reported a significant increase in Q2 2026 net sales, reaching $493.2 million, a 22.0% rise, driven by recent acquisitions and organic growth in its Currency business. Despite a slight decline in net income attributable to common shareholders for

Earnings call transcript: BlueLinx beats Q2 2026 profit forecasts, shares jump

BlueLinx Holdings significantly surpassed Q2 2026 profit forecasts, reporting adjusted EPS of $1.15 against an expected 46 cents, with revenue also slightly beating estimates. The company attributed its strong performance to market share gains, improved margins, effective cost management despite inflation, and strategic partnerships …

Crane NXT Reports Second Quarter 2026 Results

Crane NXT, a leader in authentication and traceability technologies, announced strong second-quarter 2026 financial results with sales up 22% year-over-year to $493 million and Adjusted EPS increasing 13% to $1.10. The company raised its full-year Adjusted EPS guidance to a range of $4.22 to …

RGNX Looks 33.1% Undervalued on GF Value™ Despite Possible Value Trap

Regenxbio Inc (RGNX) is set to report its Q2 earnings, with analysts forecasting a significant year-over-year revenue increase despite caution reflected in recent estimate revisions. While GuruFocus's GF Value™ suggests RGNX is 33.1% undervalued, its GF Score™ of 60 highlights weak financial strength and …

IperionX plans US redomiciliation, names Non-Executive Director

IperionX Limited plans to redomicile its ultimate parent company to the United States, specifically Texas, to align its corporate structure with its US-based operations and strategic relationships. This move aims to simplify its investment structure for US investors and enhance access to capital. Additionally, …

Nextdoor forecasts low teens 2026 revenue growth and ~10% adjusted EBITDA margin as Q3 revenue is guided to $76M-$78M

Earnings Call Insights: Nextdoor (NXDR) Q2 2026 MANAGEMENT VIEW * "Q2 was a landmark quarter for Nextdoor with the strongest financial performance in our company's history" (Co-Founder, CEO, President & Chairperson of the Board Nirav Tolia), adding that "Platform WAU reached an all-time high" …

Nextdoor (NYSE:NXDR) Shares Gap Up After Strong Earnings

11,317 Shares in NXP Semiconductors N.V. $NXPI Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC recently purchased 11,317 shares of NXP Semiconductors N.V. (NASDAQ:NXPI) valued at approximately $2.26 million, contributing to institutional investors and hedge funds owning 90.54% of the company's stock. NXP Semiconductors exceeded its quarterly earnings expectations with $3.61 adjusted EPS and …

argenx SE (ARGX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

BlueLinx Holdings Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:BXC) 2026-08-05

BlueLinx (NYSE:BXC) Trading Up 9.7% Following Strong Earnings

Are Investors Undervaluing Quanex Building Products (NX) Right Now?

Crane NXT (NYSE:CXT) Posts Earnings Results, Beats Expectations By $0.06 EPS

Morgan Stanley Maintains CNX Resources Corp(CNX.US) With Sell Rating, Maintains Target Price $32

Morgan Stanley has reiterated its Sell rating for CNX Resources Corp (CNX.US) and maintained its target price of $32. This indicates a continued cautious outlook on the company's stock from the investment bank.